Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001140361-25-005770
Filing Date
2025-02-25
Accepted
2025-02-25 07:19:33
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7287
2 EXHIBIT 99.1 ef20044253_ex99-1.htm EX-99.1 17679
  Complete submission text file 0001140361-25-005770.txt   26943
Mailing Address 701 VETERANS CIRCLE WARMINSTER PA 18974
Business Address 701 VETERANS CIRCLE WARMINSTER PA 18974 604-419-3200
Arbutus Biopharma Corp (Subject) CIK: 0001447028 (see all company filings)

EIN.: 980597776 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-85963 | Film No.: 25659394
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filed by) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SCHEDULE 13D/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)